Pterostilbene
In clinical developmentAlso known as EH-301 COMPONENT PTEROSTILBENE, 3,5-DIMETHOXY-4'-HYDROXY-TRANS-STILBENE, PHENOL, 4-((1E)-2-(3,5-DIMETHOXYPHENYL)ETHENYL)-.
Recent clinical, regulatory, research and industry developments relating to this drug.
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap.
Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- International journal of biological sciences1
- Ahmad I1
- Alshehri MA1
- Begh MZA1
- Emran TB1
- Haque MA1
- Kang S1
- Kar NR1
- Khan J1
- Centurion University of Technology and Management1
- College of Korean Medicine1
- College of Pharmacy1
- Daffodil International University1
- Department of Clinical Laboratory Sciences1
- Department of Clinical Pharmacy1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials